Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Nature Communications

Volumn 7, Issue , 2016, Pages

  Li, Chia Wei ^a   Lim, Seung Oe ^a   Xia, Weiya ^a   Lee, Heng Huan ^a   Chan, Li Chuan ^a,b   Kuo, Chu Wei ^c,d   Khoo, Kay Hooi ^d   Chang, Shih Shin ^a,b   Cha, Jong Ho ^a,e   Kim, Taewan ^a   Hsu, Jennifer L ^a,f,g   Wu, Yun ^a   Hsu, Jung Mao ^a   Yamaguchi, Hirohito ^a   Ding, Qingqing ^a   Wang, Yan ^a   Yao, Jun ^a   Lee, Cheng Chung ^c   Wu, Hsing Ju ^f   Sahin, Aysegul A ^a   Allison, James P ^a   Yu, Dihua ^a,b   Hortobagyi, Gabriel N ^a   Hung, Mien Chie ^a,b,f,g   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c ACADEMIA SINICA   (Taiwan)

^d INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^e Seoul National University   (South Korea)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

^g ASIA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CIGLITAZONE; CYCLOHEXIMIDE; EPIDERMAL GROWTH FACTOR; EPIREGULIN; ERLOTINIB; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GEFITINIB; GLYCOGEN SYNTHASE KINASE 3BETA; GRANZYME B; GREEN FLUORESCENT PROTEIN; HEMAGGLUTININ; LAPATINIB; PROGRAMMED DEATH 1 LIGAND 1; RESVERATROL; SCATTER FACTOR; SHORT HAIRPIN RNA; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TROGLITAZONE; TUNICAMYCIN; ANTINEOPLASTIC AGENT; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; CD274 PROTEIN, HUMAN; CD274 PROTEIN, MOUSE; PDCD1 PROTEIN, HUMAN; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR; QUINAZOLINE DERIVATIVE;

CANCER; DISEASE INCIDENCE; DISEASE TREATMENT; ENZYME ACTIVITY; IMMUNE RESPONSE; IMMUNE SYSTEM; LIGAND; PHYSIOLOGICAL RESPONSE; SENESCENCE; TUMOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BASAL LIKE BREAST CANCER; CANCER CELL LINE; CANCER TISSUE; CARBOXY TERMINAL SEQUENCE; CELL LYSATE; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME BINDING; ENZYME INACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TANDEM MASS SPECTROMETRY; TRANSCRIPTION INITIATION; TUMOR ASSOCIATED LEUKOCYTE; UBIQUITINATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BREAST; BREAST TUMOR; DRUG EFFECT; DRUG SCREENING; GLYCOSYLATION; IMMUNOLOGY; IMMUNOSURVEILLANCE; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR ESCAPE;

ANIMALS; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; FEMALE; GLYCOGEN SYNTHASE KINASE 3 BETA; GLYCOSYLATION; HUMANS; IMMUNOLOGIC SURVEILLANCE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; PHOSPHORYLATION; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN STABILITY; QUINAZOLINES; T-LYMPHOCYTES; TUMOR ESCAPE; UBIQUITINATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84984911573     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12632     Document Type: Article

References (42)

1. Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523, 231-235 (2015).
2. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
3. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
4. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793-800 (2002).
5. Velcheti, V. et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab. Invest. 94, 107-116 (2014).
6. Sznol, M. & Chen, L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin. Cancer Res. 19, 1021-1034 (2013).
7. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
8. Cheung, J. C. & Reithmeier, R. A. Scanning N-glycosylation mutagenesis of membrane proteins. Methods 41, 451-459 (2007).
9. Schwarz, F. & Aebi, M. Mechanisms and principles of N-linked protein glycosylation. Curr. Opin. Struct. Biol. 21, 576-582 (2011).
10. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010).
11. Helenius, A. & Aebi, M. Intracellular functions of N-linked glycans. Science 291, 2364-2369 (2001).
12. Helenius, A. & Aebi, M. Roles of N-linked glycans in the endoplasmic reticulum. Annual review of biochemistry 73, 1019-1049 (2004).
13. von Itzstein, M. et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363, 418-423 (1993).
14. Brunet, J. F. et al. A new member of the immunoglobulin superfamily-CTLA-4. Nature 328, 267-270 (1987).
15. Hudak, J. E. & Bertozzi, C. R. Glycotherapy: new advances inspire a reemergence of glycans in medicine. Chem. Biol. 21, 16-37 (2014).
16. Croci, D. O. et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 156, 744-758 (2014).
17. Doble, B. W. & Woodgett, J. R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116, 1175-1186 (2003).
18. Frame, S. & Cohen, P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359, 1-16 (2001).
19. Ding, Q. et al. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol. Cell Biol. 27, 4006-4017 (2007).
20. Zhou, B. P. et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol. 6, 931-940 (2004).
21. MacDonald, B. T., Tamai, K. & He, X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9-26 (2009).
22. Stanley, P. Golgi glycosylation. Cold Spring Harb. Perspect. Biol. 3, 1-13 (2011).
23. Vigdorovich, V. et al. Structure and T cell inhibition properties of B7 family member, B7-H3. Structure 21, 707-717 (2013).
24. Margottin-Goguet, F. et al. Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. Dev. Cell 4, 813-826 (2003).
25. Guardavaccaro, D. et al. Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev. Cell 4, 799-812 (2003).
26. Zhou, G. L. et al. Opposing roles for Akt1 and Akt2 in Rac/Pak signaling and cell migration. J. Biol. Chem. 281, 36443-36453 (2006).
27. Huang, X. et al. Crystal structure of an inactive Akt2 kinase domain. Structure 11, 21-30 (2003).
28. Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H. & Freeman, G. J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27, 111-122 (2007).
29. Yang, J. et al. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J. Immunol. 187, 1113-1119 (2011).
30. Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887-3895 (1992).
31. Yang, J. Y. et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat. Cell Biol. 10, 138-148 (2008).
32. Yamaguchi, H., Hsu, J. L. & Hung, M. C. Regulation of ubiquitination mediated protein degradation by survival kinases in cancer. Front. Oncol. 2, 15 (2012).
33. Parsa, A. T. et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13, 84-88 (2007).
34. Akbay, E. A. et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3, 1355-1363 (2013).
35. Cohen, P. & Frame, S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2, 769-776 (2001).
36. Hu, M. C. et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117, 225-237 (2004).
37. Shen, J. et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 497, 383-387 (2013).
38. Chang, C. J. et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol. 13, 317-323 (2011).
39. Lee, D. F. et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130, 440-455 (2007).
40. Lim, S. O. et al. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology 135, 2128-2140 (2008).
41. Sheppard, K. A. et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 574, 37-41 (2004).
42. Li, C. W. et al. AKT1 inhibits epithelial-to-mesenchymal transition in breast cancer through phosphorylation-dependent Twist1 degradation. Cancer Res. 76, 1451-1462 (2016).